Sernova Biotherapeutics Inc SVA.TO
TSX
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.63% | 11.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.44% | 9.83% | |||
| Operating Income | 9.44% | -9.83% | |||
| Income Before Tax | 21.69% | -35.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.06% | -39.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.06% | -39.86% | |||
| EBIT | 9.44% | -9.83% | |||
| EBITDA | 9.46% | -9.85% | |||
| EPS Basic | 28.36% | -34.00% | |||
| Normalized Basic EPS | 26.19% | -31.25% | |||
| EPS Diluted | 28.36% | -34.00% | |||
| Normalized Diluted EPS | 26.19% | -31.25% | |||
| Average Basic Shares Outstanding | 7.55% | 4.38% | |||
| Average Diluted Shares Outstanding | 7.55% | 4.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||